Accession Number: | 0001415889-23-007688 |
Date: | 2023-05-05 |
Issuer: | HALOZYME THERAPEUTICS, INC. (HALO) |
Original Submission Date: |
CONNAUGHTON BERNADETTE
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO, CA 92130
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-05-05 | A | 8,065 | a | $0.00 | 40,286 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
OPTION TO PURCHASE COMMON STOCK | 31.0 | 2023-05-05 | deemed execution date | A | 11,371 (a) | 2024-05-05 | 2033-05-05 | common stock 11,371 | $31.00 | 11,371 | direct |
ID | footnote |
---|---|
f1 | represents annual restricted stock unit ("rsu") grant under the issuer's director compensation program. each rsu represents the right to receive one share of common stock of the issuer. this grant will vest in full on the earlier of (i) may 5, 2024 and (ii) the date of the issuer's next annual meeting of stockholders. these stock units are subject to a written deferral election under the issuer's directors deferred equity compensation plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. |
f2 | represents annual stock option grant under the issuer's director compensation program. this grant will vest in full on the earlier of (i) may 5, 2024 and (ii) the date of the issuer's next annual meeting of stockholders. |